Chi-Ping Day

Staff Scientist

National Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Current US Food and Drug Administration–approved chimeric antigen receptor (CAR) T cell therapies for B cell leukemias and lymphomas target CD19, which is widely expressed across the B cell lineage, often leading to on-target, off-tumor B cell depletion, prolonged immune suppression, and antigen-negative escape in a subset of patients. In contrast, B cell receptor (BcR) signaling is essential for the survival of most mature B cell neoplasms, and BcRs carrying the immunoglobulin heavy variable gene IGHV4-34 are highly enriched in B cell malignancies compared with normal B cells. Further, self-reactive IGHV4-34 + serum autoantibodies are enriched in aggressive systemic lupus erythematosus (SLE) and other autoimmune diseases. Here, we developed CAR T cells targeting the BcR carrying IGHV4-34 (CART4-34). We found that CART4-34 showed specific cytotoxicity and cytokine secretion toward IGHV4-34 + malignant B cells. In addition, although CD19 was down-regulated upon relapse after treatment with CART19, IGHV4-34 + BcR levels remained intact upon relapse after treatment with CART4-34, suggesting reduced risk of antigen-negative escape. In IGHV4-34 + HBL1 cell line–derived xenograft mouse models, CART4-34 showed robust expansion and antitumor activity comparable to those of CART19. Optimized CAR:BcR binding using shorter CAR hinge domains improved immune synapse morphology and in vivo activity. In addition, we showed that CART4-34 could target human IGHV4-34 + SLE B cells and deplete IGHV4-34 + autoantibodies ex vivo, without targeting healthy B cells or affecting total IgG titers. In conclusion, we developed a CAR T cell product that specifically targets pathogenic B cells in lymphoid malignancies and SLE, offering potential for precision cell therapy for these indications.

Year:

2026

Spatially resolved transcriptomics (SRT) technology has enabled a new level of knowledge about tumors. Many critical tumor properties, such as invasiveness and growth, depend on both specific transcriptomic changes in tumor cells and the tumor microenvironment. However, computational methods to study clinical phenotypes of spatial regions, such as hazard and drug response, have not yet been developed. Since clinical phenotypes are measured at the patient level and not at the level of spatial regions, such a method would require transferring knowledge from the patient level domain to the spot level domain. To overcome this challenge, we developed SpacePhenotyper. Our approach uses algebraic spectral techniques to transfer the predictive relationship between gene expression and clinical phenotypes from bulk gene expression data to SRT data. Our approach captures a gene expression pattern that is predictive of the phenotype of interest in the form of a vector, the “Eigen-Patient,” which is then used to quantify the phenotype in spatial spots. After extensively validating SpacePhenotyper on simulated and real data, we utilize it to study how the spatial heterogeneity of breast cancer tumors influences residual cancer burden after treatment. By assigning relative quantities of clinical phenotypes to spatial locations, SpacePhenotyper has proven a powerful tool for the identification and interpretation of transcriptional changes over spatial regions and of spatially-regulated patterns of cellular states. SpacePhenotyper is implemented in Python. The source code and data sets used for and generated during this study are available at https://github.com/ncbi/SpacePhenotyper

Year:

2025

Clinical management of patients with ovarian granulosa cell tumor (GCT) remains poor. Sirtuin-1 (SIRT1), a deacetylase enzyme involved in the regulation of tumor growth and metastasis, may represent a therapeutic target because of the availability of selective pharmacologic inhibitors with minimal toxicity. We assessed the possible overexpression of SIRT1 during tumorigenesis by Western blotting and IHC. We tested the effects of SIRT1 inhibition by EX-527 on growth, proliferation, death, migration, metabolism, and gene expression by RNA sequencing in vitro on three GCT cell lines (AT29, KGN, and COV434). Tumor growth in response to EX-527 treatment was examined in nude mice carrying subcutaneous GCT cell grafts using an electronic caliper and in GCT of AT83 mice by three-dimensional ultrasound imaging system. SIRT1 abundance increased during tumorigenesis. In vitro treatment with EX-527 efficiently reduced cell growth , either by inducing apoptosis or by inhibiting proliferation. EX-527 induced alterations in mTOR-, Myc-, and E2F-driven pathways, and in those controlling cell metabolism and oxidative stress. The administration of this treatment for 4 weeks efficiently reduced tumor progression in vivo . Inhibition of SIRT1 activity may have GCT growth suppressive effects, providing a rationale for evaluating the therapeutic potential of drugs targeting SIRT1 in patients.

Year:

2025

Despite the promising results of immune checkpoint blockade (ICB) therapy, outcomes for patients with brain metastasis (BrM) remain poor. Identifying resistance mechanisms has been hindered by limited access to patient samples and relevant preclinical models. Here, we developed two mouse melanoma BrM models that recapitulate the disparate responses to ICB seen in patients. We demonstrate that these models capture the cellular and molecular complexity of human disease and reveal key factors shaping the tumor microenvironment and influencing ICB response. BR1-responsive tumor cells express inflammatory programs that polarize microglia into reactive states, eliciting robust T cell recruitment. In contrast, BR3-resistant melanoma cells are enriched in neurological programs and exploit tolerance mechanisms to maintain microglia homeostasis and limit T cell infiltration. In humans, BR1 and BR3 expression signatures correlate positively or negatively with T cell infiltration and BrM patient outcomes, respectively. Our study provides clinically relevant models and uncovers mechanistic insights into BrM ICB responses, offering potential biomarkers and therapeutic targets to improve therapy efficacy.

Year:

2024

Collaborators (16)

David Levens

Senior investigator

National Institutes of Health

UNITED STATES
View details

Stéphanie Chauvin

Université Paris Cité

FRANCE
View details

Teresa Przytycka

senior investigator

National Institutes of Health

UNITED STATES
View details

Kostas Stamatopoulos

Visiting Professor

Karolinska Institutet

SWEDEN
View details

E John Wherry

Professor

University of Pennsylvania

UNITED STATES
View details

Sridhar Hannenhalli

Senior Investigator

National Cancer Institute

UNITED STATES
View details

Vijay Bhoj

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Andreas Agathangelidis

Assistant Professor

National and Kapodistrian University of Athens

GREECE
View details

Stephen Schuster

Professor, Clinician-Educator

Hospital of the University of Pennsylvania

UNITED STATES
View details

Vishaka Datta

National Cancer Institute

UNITED STATES
View details

Amélie Daugherty-Lopès

Senior Scientist

University of Virginia

UNITED STATES
View details

Romina Elizabeth Araya

Assistant Research Professor

George Washington University

UNITED STATES
View details

Paolo Ghia

-

ITALY
View details

Marco Ruella

PI

University of Pennsylvania

UNITED STATES
View details

Ignacio Sanz

Professor

Emory University

UNITED STATES
View details

Urbain Weyemi

National Institutes of Health

UNITED STATES
View details